Orla Dolan

And that's what makes it so, so amazing.

Yeah, so the standard of care for, these were all patients who were stage three, so they had advanced disease and surgery would have been the first thing they would normally have and then an immunotherapy.

And what they did was 50 patients would have got standard surgery and immunotherapy and then 107 got this new vaccine added in to, like I said, prime and kind of give this kind of seek heating targets for the immune system to go after.

And so what you saw then was this huge change.

So five years later, 70% of the people who got the vaccine were still cancer free compared to 49% of the people who only got the immunotherapy alone.

And so that was an enormous change.

And what was amazing is it lasted because these are results of patients five years after that treatment.

I think, look, the more money we put into research, the more we understand about the disease, the more these things can advance.

I think, you know, we talk a lot about technology and advances that technology is catching up with that now so that we're able to do these kind of advanced techniques.

But what I think is also amazing about this and why people should be really positive about it is that the result of a phase three trial for a thousand patients is already finished and they're analyzing that data now.

So, you know, then they will go to the FDA.

So this isn't 10 years out.

I think if they show true in the next stage of that trial, this will come sooner rather than later.

Yes.

You know, I mean, if you look at what they what the team we're talking about is that they're literally at the data analysis stage now where they'll have compared it to standard of care.

And if it's if it holds true, which, you know, all the rumblings are very good, then it should you know, they'll have to go to the FDA, which is another step.

But it's not that far out there.

The thing about ASCO, though, is they've produced a lot of amazing data.

There was another one about pancreatic cancer.

And I do think people should remember that the results they're presenting today probably started in research five or 10 years ago.